Overview
SCIENTIFIC SCORE
Moderately Effective
Based on 7 Researches
8.3
USERS' SCORE
Good
Based on 5 Reviews
8.3
Supplement Facts
Serving Size: 2 Capsules
Amount Per Serving
%DV
Mood Probiotic BlendLactobacillus acidophilusLactobacillus plantarumLactobacillus helveticus R0052Lactobacillus paracaseiLactobacillus caseiLactobacillus brevisLactobacillus rhamnosusLactobacillus bulgaricusLactobacillus gasseriLactobacillus salivariusTotal Lacto Cultures (45 Billion CFU)Bifidobacterium lactisBifidobacterium longum R0175Bifidobacterium bifidumBifidobacterium breveBifidobacterium infantisBifidobacterium longumTotal Bifido Cultures (5 Billion CFU)
200 mg
+
Total Probiotic Cultures
50 Billion CFU¹
Stress Support BlendOrganic Ashwagandha (root), Blueberry (fruit)
350 mg
+
Organic Prebiotic Fiber BlendOrganic Potato [Resistant Starch] (tuber), Organic Acacia Fiber (A. senegal)
675 mg
+
Top Medical Research Studies
8
We explored an innovative approach to treating glioblastoma, the most common malignant brain tumor, by utilizing docosahexaenoic acid (DHA) liposomes. These liposomes were created using a microfluidic system that allowed for fine-tuning various properties, which could enhance their effectiveness in targeting tumor cells.
Our findings revealed that these DHA liposomes, ranging in size from 80 nm to 130 nm, were successfully taken up by glioblastoma cells. This uptake was promising, as we saw a reduction in the viability of these cancerous cells. Interestingly, we also observed that DHA liposomes were significantly better at triggering cell death mechanisms compared to free DHA, specifically through pathways that involved caspase-3.
Overall, our study suggests that these microfluidic-derived DHA liposomes might offer new avenues for developing therapies using omega-3 fatty acids against brain tumors, potentially leading to more effective treatment options in the future.
Our findings revealed that these DHA liposomes, ranging in size from 80 nm to 130 nm, were successfully taken up by glioblastoma cells. This uptake was promising, as we saw a reduction in the viability of these cancerous cells. Interestingly, we also observed that DHA liposomes were significantly better at triggering cell death mechanisms compared to free DHA, specifically through pathways that involved caspase-3.
Overall, our study suggests that these microfluidic-derived DHA liposomes might offer new avenues for developing therapies using omega-3 fatty acids against brain tumors, potentially leading to more effective treatment options in the future.
Read More
8
We investigated how docosahexaenoic acid (DHA) impacts glioblastoma, a type of aggressive brain tumor notorious for its poor outcomes. The focus was on neural stem-like cells within these tumors, as they are known to contribute to drug resistance and promote the heterogeneity of the tumor.
Our research involved examining patient-derived glioblastoma neural stem-like cells grown in neurosphere cultures. We wanted to see how treatments with levels of DHA and arachidonic acid (AA) would affect the fatty acid profiles of these cells. Notably, we discovered that DHA treatment increased both the levels of DHA and the ratio of DHA to AA in these cells, with the assistance of brain fatty acid-binding protein (FABP7) which plays a crucial role in facilitating the uptake of DHA.
An interesting finding was that as the cells absorbed more DHA, their ability to migrate diminished. This could signal a potential therapeutic avenue where increasing DHA in glioblastoma could restrain the aggressive behavior of these neural stem-like cells, potentially leading to better outcomes for patients.
More research will be essential to fully understand the implications of this increased DHA content in the tumor microenvironment and its overall effects on the progression of glioblastoma.
Our research involved examining patient-derived glioblastoma neural stem-like cells grown in neurosphere cultures. We wanted to see how treatments with levels of DHA and arachidonic acid (AA) would affect the fatty acid profiles of these cells. Notably, we discovered that DHA treatment increased both the levels of DHA and the ratio of DHA to AA in these cells, with the assistance of brain fatty acid-binding protein (FABP7) which plays a crucial role in facilitating the uptake of DHA.
An interesting finding was that as the cells absorbed more DHA, their ability to migrate diminished. This could signal a potential therapeutic avenue where increasing DHA in glioblastoma could restrain the aggressive behavior of these neural stem-like cells, potentially leading to better outcomes for patients.
More research will be essential to fully understand the implications of this increased DHA content in the tumor microenvironment and its overall effects on the progression of glioblastoma.
Read More
8
We investigated the role of docosahexaenoic acid (DHA) in targeting glioblastoma, a challenging brain tumor with limited treatment options. By utilizing a special technique to create DHA liposomes, we aimed to reduce the inflammatory environment surrounding the tumor. This innovative approach allowed for a targeted delivery of DHA to the affected areas.
Through our research, we observed that these DHA liposomes were quickly taken up by macrophages, a type of immune cell, without causing any harm to them. We also discovered that these liposomes significantly lowered the activity of genes associated with inflammation and decreased the release of key inflammatory cytokines in both stimulated macrophages and glioblastoma cells.
Interestingly, while the DHA liposomes showed effectiveness in regulating inflammation, they did not notably change the expression of a certain anti-inflammatory gene in macrophages. Furthermore, our findings indicated that using DHA in liposome form was more effective than administering it freely.
Overall, our study highlights a promising strategy for using DHA liposomes to target glioblastoma and its inflammatory microenvironment. This innovative approach could lead to new treatment options for patients facing this aggressive type of brain cancer.
Through our research, we observed that these DHA liposomes were quickly taken up by macrophages, a type of immune cell, without causing any harm to them. We also discovered that these liposomes significantly lowered the activity of genes associated with inflammation and decreased the release of key inflammatory cytokines in both stimulated macrophages and glioblastoma cells.
Interestingly, while the DHA liposomes showed effectiveness in regulating inflammation, they did not notably change the expression of a certain anti-inflammatory gene in macrophages. Furthermore, our findings indicated that using DHA in liposome form was more effective than administering it freely.
Overall, our study highlights a promising strategy for using DHA liposomes to target glioblastoma and its inflammatory microenvironment. This innovative approach could lead to new treatment options for patients facing this aggressive type of brain cancer.
Read More
Most Useful Reviews
7.5
Enhanced relaxation
2 people found this helpful
Wonderful probiotic! This excellent product significantly enhances the body and helps one feel more relaxed. It effectively regulates the entire brain.
Read More
9
Mood improvement
1 people found this helpful
This product offers trusted potency without needing refrigeration. It ensures improved mood, digestive support, and immune system benefits, featuring 50 billion probiotics across 16 strains, which promotes emotional well-being and relaxation. Backed by modern science on gut-brain health, it includes clinically studied probiotics and natural ingredients to enhance mood and relaxation effectively.
Read More
8
Positive effects noted
1 people found this helpful
This product is genuinely effective. We haven’t found a better solution for achieving a good mood and lightness! It offers numerous positive effects for brain functioning, and I’m not ready to stop using it.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 7 Researches
8.3
- All Researches
9
We examined the effects of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)—two types of omega-3 fatty acids—on medulloblastoma (MB), a common and aggressive brain tumor in children. Our study involved treating MB cell lines with these fatty acids and also used a mouse model to assess their effects in a living organism. We randomized mice with implanted MB cells into three groups: one receiving DHA, one receiving a combination of DHA and EPA, and a control group.
Through our experiments, we found that DHA and EPA could significantly reduce the secretion of prostaglandin E2, a compound that can promote tumor growth. In doses that we tested, these omega-3 fatty acids impaired the viability and colony formation abilities of MB cells while also increasing cell death. Additionally, we observed that DHA treatment led to reduced tumor size in mice, and we noticed a decrease in inflammatory markers like prostacyclin in treated tumors compared to those in control mice.
Further analysis through RNA sequencing highlighted 10 genes that were commonly downregulated in tumors treated with omega-3 fatty acids. Among them, CRYAB stood out as the most significantly altered gene, a finding we confirmed through immunohistochemistry. This suggests a protective role of these fatty acids in targeting inflammatory responses in the tumor microenvironment, potentially offering a new avenue for medulloblastoma treatment in conjunction with standard therapies.
Through our experiments, we found that DHA and EPA could significantly reduce the secretion of prostaglandin E2, a compound that can promote tumor growth. In doses that we tested, these omega-3 fatty acids impaired the viability and colony formation abilities of MB cells while also increasing cell death. Additionally, we observed that DHA treatment led to reduced tumor size in mice, and we noticed a decrease in inflammatory markers like prostacyclin in treated tumors compared to those in control mice.
Further analysis through RNA sequencing highlighted 10 genes that were commonly downregulated in tumors treated with omega-3 fatty acids. Among them, CRYAB stood out as the most significantly altered gene, a finding we confirmed through immunohistochemistry. This suggests a protective role of these fatty acids in targeting inflammatory responses in the tumor microenvironment, potentially offering a new avenue for medulloblastoma treatment in conjunction with standard therapies.
Read More
9
We investigated the potential of docosahexaenoic acid (DHA) as part of a novel treatment for glioblastoma, a challenging brain tumor. Our study involved formulating mebendazole (MBZ) microemulsions that included DHA along with other compounds, assessing their effectiveness in an orthotopic C6 rat model.
The formulations were carefully characterized before testing. We found that one formulation—composed of oleic acid and labrafil, with a 0.1% mucoadhesive agent—showed promising results. Importantly, there were no observable toxic effects on the nasal epithelium, suggesting the safety of this delivery method.
Furthermore, we observed improved survival rates in the treated rats compared to the control group. Our findings implied that this combined approach with DHA and MBZ microemulsions might offer a new avenue for glioblastoma treatment, although we noted that the contribution of DHA alone couldn't be fully isolated.
Overall, our research encourages the exploration of innovative strategies to enhance the treatment of malignant brain tumors through targeted intranasal delivery.
The formulations were carefully characterized before testing. We found that one formulation—composed of oleic acid and labrafil, with a 0.1% mucoadhesive agent—showed promising results. Importantly, there were no observable toxic effects on the nasal epithelium, suggesting the safety of this delivery method.
Furthermore, we observed improved survival rates in the treated rats compared to the control group. Our findings implied that this combined approach with DHA and MBZ microemulsions might offer a new avenue for glioblastoma treatment, although we noted that the contribution of DHA alone couldn't be fully isolated.
Overall, our research encourages the exploration of innovative strategies to enhance the treatment of malignant brain tumors through targeted intranasal delivery.
Read More
8
We investigated the role of docosahexaenoic acid (DHA) in targeting glioblastoma, a challenging brain tumor with limited treatment options. By utilizing a special technique to create DHA liposomes, we aimed to reduce the inflammatory environment surrounding the tumor. This innovative approach allowed for a targeted delivery of DHA to the affected areas.
Through our research, we observed that these DHA liposomes were quickly taken up by macrophages, a type of immune cell, without causing any harm to them. We also discovered that these liposomes significantly lowered the activity of genes associated with inflammation and decreased the release of key inflammatory cytokines in both stimulated macrophages and glioblastoma cells.
Interestingly, while the DHA liposomes showed effectiveness in regulating inflammation, they did not notably change the expression of a certain anti-inflammatory gene in macrophages. Furthermore, our findings indicated that using DHA in liposome form was more effective than administering it freely.
Overall, our study highlights a promising strategy for using DHA liposomes to target glioblastoma and its inflammatory microenvironment. This innovative approach could lead to new treatment options for patients facing this aggressive type of brain cancer.
Through our research, we observed that these DHA liposomes were quickly taken up by macrophages, a type of immune cell, without causing any harm to them. We also discovered that these liposomes significantly lowered the activity of genes associated with inflammation and decreased the release of key inflammatory cytokines in both stimulated macrophages and glioblastoma cells.
Interestingly, while the DHA liposomes showed effectiveness in regulating inflammation, they did not notably change the expression of a certain anti-inflammatory gene in macrophages. Furthermore, our findings indicated that using DHA in liposome form was more effective than administering it freely.
Overall, our study highlights a promising strategy for using DHA liposomes to target glioblastoma and its inflammatory microenvironment. This innovative approach could lead to new treatment options for patients facing this aggressive type of brain cancer.
Read More
8
We explored an innovative approach to treating glioblastoma, the most common malignant brain tumor, by utilizing docosahexaenoic acid (DHA) liposomes. These liposomes were created using a microfluidic system that allowed for fine-tuning various properties, which could enhance their effectiveness in targeting tumor cells.
Our findings revealed that these DHA liposomes, ranging in size from 80 nm to 130 nm, were successfully taken up by glioblastoma cells. This uptake was promising, as we saw a reduction in the viability of these cancerous cells. Interestingly, we also observed that DHA liposomes were significantly better at triggering cell death mechanisms compared to free DHA, specifically through pathways that involved caspase-3.
Overall, our study suggests that these microfluidic-derived DHA liposomes might offer new avenues for developing therapies using omega-3 fatty acids against brain tumors, potentially leading to more effective treatment options in the future.
Our findings revealed that these DHA liposomes, ranging in size from 80 nm to 130 nm, were successfully taken up by glioblastoma cells. This uptake was promising, as we saw a reduction in the viability of these cancerous cells. Interestingly, we also observed that DHA liposomes were significantly better at triggering cell death mechanisms compared to free DHA, specifically through pathways that involved caspase-3.
Overall, our study suggests that these microfluidic-derived DHA liposomes might offer new avenues for developing therapies using omega-3 fatty acids against brain tumors, potentially leading to more effective treatment options in the future.
Read More
8
We investigated how docosahexaenoic acid (DHA) impacts glioblastoma, a type of aggressive brain tumor notorious for its poor outcomes. The focus was on neural stem-like cells within these tumors, as they are known to contribute to drug resistance and promote the heterogeneity of the tumor.
Our research involved examining patient-derived glioblastoma neural stem-like cells grown in neurosphere cultures. We wanted to see how treatments with levels of DHA and arachidonic acid (AA) would affect the fatty acid profiles of these cells. Notably, we discovered that DHA treatment increased both the levels of DHA and the ratio of DHA to AA in these cells, with the assistance of brain fatty acid-binding protein (FABP7) which plays a crucial role in facilitating the uptake of DHA.
An interesting finding was that as the cells absorbed more DHA, their ability to migrate diminished. This could signal a potential therapeutic avenue where increasing DHA in glioblastoma could restrain the aggressive behavior of these neural stem-like cells, potentially leading to better outcomes for patients.
More research will be essential to fully understand the implications of this increased DHA content in the tumor microenvironment and its overall effects on the progression of glioblastoma.
Our research involved examining patient-derived glioblastoma neural stem-like cells grown in neurosphere cultures. We wanted to see how treatments with levels of DHA and arachidonic acid (AA) would affect the fatty acid profiles of these cells. Notably, we discovered that DHA treatment increased both the levels of DHA and the ratio of DHA to AA in these cells, with the assistance of brain fatty acid-binding protein (FABP7) which plays a crucial role in facilitating the uptake of DHA.
An interesting finding was that as the cells absorbed more DHA, their ability to migrate diminished. This could signal a potential therapeutic avenue where increasing DHA in glioblastoma could restrain the aggressive behavior of these neural stem-like cells, potentially leading to better outcomes for patients.
More research will be essential to fully understand the implications of this increased DHA content in the tumor microenvironment and its overall effects on the progression of glioblastoma.
Read More
User Reviews
USERS' SCORE
Good
Based on 5 Reviews
8.3
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Enhanced relaxation
2 people found this helpful
Wonderful probiotic! This excellent product significantly enhances the body and helps one feel more relaxed. It effectively regulates the entire brain.
Read More
9
Mood improvement
1 people found this helpful
This product offers trusted potency without needing refrigeration. It ensures improved mood, digestive support, and immune system benefits, featuring 50 billion probiotics across 16 strains, which promotes emotional well-being and relaxation. Backed by modern science on gut-brain health, it includes clinically studied probiotics and natural ingredients to enhance mood and relaxation effectively.
Read More
8
Positive effects noted
1 people found this helpful
This product is genuinely effective. We haven’t found a better solution for achieving a good mood and lightness! It offers numerous positive effects for brain functioning, and I’m not ready to stop using it.
Read More
7.5
Reduced stress levels
3 people found this helpful
Following extensive research to find a probiotic supplement that enhances my mood via the gut-brain axis, I discovered this product. I confess I wasn’t expecting any benefits, but surprisingly, I’ve experienced reduced stress and anxiety, increased energy, and an overall improvement in health and mood. Thus, I have ordered my second bottle!
Read More
7
Elevated mood
1 people found this helpful
Noticeable benefits! After thorough research for a probiotic supplement that boosts my mood through the gut-brain axis, I found this one. Honestly, I didn’t expect any positive effects, but surprisingly, I've felt much less stressed and more energetic than usual, resulting in an overall better mood. I've just ordered my second bottle!
Read More
Frequently Asked Questions
7.5
Reduced stress levels
3 people found this helpful
Following extensive research to find a probiotic supplement that enhances my mood via the gut-brain axis, I discovered this product. I confess I wasn’t expecting any benefits, but surprisingly, I’ve experienced reduced stress and anxiety, increased energy, and an overall improvement in health and mood. Thus, I have ordered my second bottle!
7
Elevated mood
1 people found this helpful
Noticeable benefits! After thorough research for a probiotic supplement that boosts my mood through the gut-brain axis, I found this one. Honestly, I didn’t expect any positive effects, but surprisingly, I've felt much less stressed and more energetic than usual, resulting in an overall better mood. I've just ordered my second bottle!
8
Positive effects noted
1 people found this helpful
This product is genuinely effective. We haven’t found a better solution for achieving a good mood and lightness! It offers numerous positive effects for brain functioning, and I’m not ready to stop using it.
8
We explored an innovative approach to treating glioblastoma, the most common malignant brain tumor, by utilizing docosahexaenoic acid (DHA) liposomes. These liposomes were created using a microfluidic system that allowed for fine-tuning various properties, which could enhance their effectiveness in targeting tumor cells.
Our findings revealed that these DHA liposomes, ranging in size from 80 nm to 130 nm, were successfully taken up by glioblastoma cells. This uptake was promising, as we saw a reduction in the viability of these cancerous cells. Interestingly, we also observed that DHA liposomes were significantly better at triggering cell death mechanisms compared to free DHA, specifically through pathways that involved caspase-3.
Overall, our study suggests that these microfluidic-derived DHA liposomes might offer new avenues for developing therapies using omega-3 fatty acids against brain tumors, potentially leading to more effective treatment options in the future.
Our findings revealed that these DHA liposomes, ranging in size from 80 nm to 130 nm, were successfully taken up by glioblastoma cells. This uptake was promising, as we saw a reduction in the viability of these cancerous cells. Interestingly, we also observed that DHA liposomes were significantly better at triggering cell death mechanisms compared to free DHA, specifically through pathways that involved caspase-3.
Overall, our study suggests that these microfluidic-derived DHA liposomes might offer new avenues for developing therapies using omega-3 fatty acids against brain tumors, potentially leading to more effective treatment options in the future.
8
We investigated how docosahexaenoic acid (DHA), a key omega-3 fatty acid found in the human brain, impacts glioblastoma multiforme (GBM) cells. Our findings revealed that high doses of DHA can indeed induce a process known as cellular autophagy in two specific GBM cell lines, U251 and U118, while lower doses did not show the same effect.
We observed that after treating the U251 cells with a high dose of DHA across various time intervals (12, 24, and 48 hours), the levels of a protein called SQSTM1/p62 exhibited an interesting pattern. Initially, the protein levels decreased at 12 and 24 hours, but increased again by 48 hours. In U118 cells, however, SQSTM1/p62 levels rose consistently at all measured time points.
Furthermore, we discovered that the mRNA levels of SQSTM1/p62 increased in both cell lines following DHA treatment. This indicates that DHA encourages the production of SQSTM1/p62. Notably, when we reduced the levels of SQSTM1/p62 using a designated siRNA, the autophagy triggered by DHA was lessened in both cell lines. This led us to conclude that SQSTM1/p62 plays a significant regulatory role in the DHA-induced autophagic process.
Overall, high-dose DHA was shown to effectively promote autophagy in glioblastoma cells. However, the broader implications for tumor reduction are still unclear and warrant further clinical investigation.
We observed that after treating the U251 cells with a high dose of DHA across various time intervals (12, 24, and 48 hours), the levels of a protein called SQSTM1/p62 exhibited an interesting pattern. Initially, the protein levels decreased at 12 and 24 hours, but increased again by 48 hours. In U118 cells, however, SQSTM1/p62 levels rose consistently at all measured time points.
Furthermore, we discovered that the mRNA levels of SQSTM1/p62 increased in both cell lines following DHA treatment. This indicates that DHA encourages the production of SQSTM1/p62. Notably, when we reduced the levels of SQSTM1/p62 using a designated siRNA, the autophagy triggered by DHA was lessened in both cell lines. This led us to conclude that SQSTM1/p62 plays a significant regulatory role in the DHA-induced autophagic process.
Overall, high-dose DHA was shown to effectively promote autophagy in glioblastoma cells. However, the broader implications for tumor reduction are still unclear and warrant further clinical investigation.
9
We examined the effects of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)—two types of omega-3 fatty acids—on medulloblastoma (MB), a common and aggressive brain tumor in children. Our study involved treating MB cell lines with these fatty acids and also used a mouse model to assess their effects in a living organism. We randomized mice with implanted MB cells into three groups: one receiving DHA, one receiving a combination of DHA and EPA, and a control group.
Through our experiments, we found that DHA and EPA could significantly reduce the secretion of prostaglandin E2, a compound that can promote tumor growth. In doses that we tested, these omega-3 fatty acids impaired the viability and colony formation abilities of MB cells while also increasing cell death. Additionally, we observed that DHA treatment led to reduced tumor size in mice, and we noticed a decrease in inflammatory markers like prostacyclin in treated tumors compared to those in control mice.
Further analysis through RNA sequencing highlighted 10 genes that were commonly downregulated in tumors treated with omega-3 fatty acids. Among them, CRYAB stood out as the most significantly altered gene, a finding we confirmed through immunohistochemistry. This suggests a protective role of these fatty acids in targeting inflammatory responses in the tumor microenvironment, potentially offering a new avenue for medulloblastoma treatment in conjunction with standard therapies.
Through our experiments, we found that DHA and EPA could significantly reduce the secretion of prostaglandin E2, a compound that can promote tumor growth. In doses that we tested, these omega-3 fatty acids impaired the viability and colony formation abilities of MB cells while also increasing cell death. Additionally, we observed that DHA treatment led to reduced tumor size in mice, and we noticed a decrease in inflammatory markers like prostacyclin in treated tumors compared to those in control mice.
Further analysis through RNA sequencing highlighted 10 genes that were commonly downregulated in tumors treated with omega-3 fatty acids. Among them, CRYAB stood out as the most significantly altered gene, a finding we confirmed through immunohistochemistry. This suggests a protective role of these fatty acids in targeting inflammatory responses in the tumor microenvironment, potentially offering a new avenue for medulloblastoma treatment in conjunction with standard therapies.
8
We investigated how docosahexaenoic acid (DHA) impacts glioblastoma, a type of aggressive brain tumor notorious for its poor outcomes. The focus was on neural stem-like cells within these tumors, as they are known to contribute to drug resistance and promote the heterogeneity of the tumor.
Our research involved examining patient-derived glioblastoma neural stem-like cells grown in neurosphere cultures. We wanted to see how treatments with levels of DHA and arachidonic acid (AA) would affect the fatty acid profiles of these cells. Notably, we discovered that DHA treatment increased both the levels of DHA and the ratio of DHA to AA in these cells, with the assistance of brain fatty acid-binding protein (FABP7) which plays a crucial role in facilitating the uptake of DHA.
An interesting finding was that as the cells absorbed more DHA, their ability to migrate diminished. This could signal a potential therapeutic avenue where increasing DHA in glioblastoma could restrain the aggressive behavior of these neural stem-like cells, potentially leading to better outcomes for patients.
More research will be essential to fully understand the implications of this increased DHA content in the tumor microenvironment and its overall effects on the progression of glioblastoma.
Our research involved examining patient-derived glioblastoma neural stem-like cells grown in neurosphere cultures. We wanted to see how treatments with levels of DHA and arachidonic acid (AA) would affect the fatty acid profiles of these cells. Notably, we discovered that DHA treatment increased both the levels of DHA and the ratio of DHA to AA in these cells, with the assistance of brain fatty acid-binding protein (FABP7) which plays a crucial role in facilitating the uptake of DHA.
An interesting finding was that as the cells absorbed more DHA, their ability to migrate diminished. This could signal a potential therapeutic avenue where increasing DHA in glioblastoma could restrain the aggressive behavior of these neural stem-like cells, potentially leading to better outcomes for patients.
More research will be essential to fully understand the implications of this increased DHA content in the tumor microenvironment and its overall effects on the progression of glioblastoma.
References
- Mendanha D, Casanova MR, Gimondi S, Ferreira H, Neves NM. Microfluidic-Derived Docosahexaenoic Acid Liposomes for Targeting Glioblastoma and Its Inflammatory Microenvironment. ACS Appl Mater Interfaces. 2024;16:40543. doi:10.1021/acsami.4c01368
- Mendanha D, Gimondi S, Costa BM, Ferreira H, Neves NM. Microfluidic-derived docosahexaenoic acid liposomes for glioblastoma therapy. Nanomedicine. 2023;53:102704. doi:10.1016/j.nano.2023.102704
- Ljungblad L, Bergqvist F, Tümmler C, Madawala S, Olsen TK, et al. Omega-3 fatty acids decrease CRYAB, production of oncogenic prostaglandin E and suppress tumor growth in medulloblastoma. Life Sci. 2022;295:120394. doi:10.1016/j.lfs.2022.120394
- Choi WS, Xu X, Goruk S, Wang Y, Patel S, et al. FABP7 Facilitates Uptake of Docosahexaenoic Acid in Glioblastoma Neural Stem-like Cells. Nutrients. 2021;13. doi:10.3390/nu13082664
- Xu X, Wang Y, Choi WS, Sun X, Godbout R. Super resolution microscopy reveals DHA-dependent alterations in glioblastoma membrane remodelling and cell migration. Nanoscale. 2021;13:9706. doi:10.1039/d1nr02128a
- Mena-Hernández J, Jung-Cook H, Llaguno-Munive M, García-López P, Ganem-Rondero A, et al. Preparation and Evaluation of Mebendazole Microemulsion for Intranasal Delivery: an Alternative Approach for Glioblastoma Treatment. AAPS PharmSciTech. 2020;21:264. doi:10.1208/s12249-020-01805-x
- Tan X, Zou L, Qin J, Xia D, Zhou Y, et al. SQSTM1/p62 is involved in docosahexaenoic acid-induced cellular autophagy in glioblastoma cell lines. In Vitro Cell Dev Biol Anim. 2019;55:703. doi:10.1007/s11626-019-00387-8
